Seventeen drugs, one sample: analyzing multiple anti-TB drugs simultaneously using one method
In conclusion, we developed a method to analyze 17 anti-TB drugs simultaneously in one sample of plasma, serum or saliva: all first-line, BPaLM, and 9m all oral regimen for MDR/RR-TB drugs, and 63% of the longer MDR-TB regimen drugs. This method will save time and will further optimize therapeutic drug monitoring. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Bolhuis, M. S., Jongedijk, E. M., Akkerman, O. W., Touw, D. J., Sturkenboom, M. G. G. Tags: Tuberculosis and non-tuberculous mycobacterial diseases Source Type: research

Tuberculous meningoencephalitis complicate with mielitis
Conclusions: Patients with myelitis often have poor outcomes. In the presented case, the patient had a favorable clinical response to the treatment, but despite the correctly administered antituberculous treatment, the inflammation in the CSF continues to persist. Further research on the pathogenesis of TB myelitis will be helpful to provide potential effective therapy to these patients. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Caliman-Sturdza, O. A. Tags: Tuberculosis and non-tuberculous mycobacterial diseases Source Type: research

Contemporary pharmacologic treatments of MRSA for hospitalized adults: rationale for vancomycin versus non-vancomycin therapies as first line agents
Expert Rev Anti Infect Ther. 2023 Oct 24. doi: 10.1080/14787210.2023.2275663. Online ahead of print.ABSTRACTINTRODUCTION: Methicillin-resistant Staphylococcus aureus (MRSA) remains an important pathogen in the hospital setting and causes significant morbidity and mortality each year. Since the initial discovery over 60 years ago, vancomycin has remained a first-line treatment for many different types of MRSA infections. However, significant concerns related to target attainment and nephrotoxicity have spurred efforts to develop more effective agents in the last two decades.AREAS COVERED: Newer anti-MRSA antibiotics that ha...
Source: Expert Review of Anti-Infective Therapy - October 25, 2023 Category: Infectious Diseases Authors: Jack Chang Ardita Tasellari Jamie L Wagner Marc H Scheetz Source Type: research

A Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneously Determining Meropenem and Linezolid in Blood and Cerebrospinal Fluid
Ann Lab Med. 2023 Oct 23. doi: 10.3343/alm.2023.0250. Online ahead of print.ABSTRACTAntibiotic therapy requires appropriate dosage of drugs for effective treatment. Too low antibiotic concentrations may lead to treatment failure and the development of resistant pathogens, whereas overdosing may cause neurological side effects or hemolytic diseases. Meropenem and linezolid are used only in the treatment of serious infections or when other antibiotics are no longer effective as well as for treating central nervous system infections. It is difficult or sometimes even impossible to predict the relation between dosing of antibi...
Source: Annals of Laboratory Medicine - October 23, 2023 Category: Laboratory Medicine Authors: Joanna Berska Jolanta Bugajska Krystyna Sztefko Source Type: research

Efficacy and Safety of Different Antibiotic Therapies for Bone and Joint Infections: A Network Meta-analysis of Randomized Controlled Trials
CONCLUSION: Linezolid appeared to be the most promising treatment regimen for staphylococcal bone and joint infections. However, due to the overall limited evidence, the research results need further high-quality RCTs for confirmation.PMID:37861039 | DOI:10.2174/0113816128236536231010051130 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - October 20, 2023 Category: Drugs & Pharmacology Authors: Xiangwen Shi Yipeng Wu Haonan Ni Minzheng Guo Qi Cheng Yongqing Xu Source Type: research

Efficacy and Safety of Different Antibiotic Therapies for Bone and Joint Infections: A Network Meta-analysis of Randomized Controlled Trials
CONCLUSION: Linezolid appeared to be the most promising treatment regimen for staphylococcal bone and joint infections. However, due to the overall limited evidence, the research results need further high-quality RCTs for confirmation.PMID:37861039 | DOI:10.2174/0113816128236536231010051130 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - October 20, 2023 Category: Drugs & Pharmacology Authors: Xiangwen Shi Yipeng Wu Haonan Ni Minzheng Guo Qi Cheng Yongqing Xu Source Type: research

Efficacy and Safety of Different Antibiotic Therapies for Bone and Joint Infections: A Network Meta-analysis of Randomized Controlled Trials
CONCLUSION: Linezolid appeared to be the most promising treatment regimen for staphylococcal bone and joint infections. However, due to the overall limited evidence, the research results need further high-quality RCTs for confirmation.PMID:37861039 | DOI:10.2174/0113816128236536231010051130 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - October 20, 2023 Category: Drugs & Pharmacology Authors: Xiangwen Shi Yipeng Wu Haonan Ni Minzheng Guo Qi Cheng Yongqing Xu Source Type: research

Efficacy and Safety of Different Antibiotic Therapies for Bone and Joint Infections: A Network Meta-analysis of Randomized Controlled Trials
CONCLUSION: Linezolid appeared to be the most promising treatment regimen for staphylococcal bone and joint infections. However, due to the overall limited evidence, the research results need further high-quality RCTs for confirmation.PMID:37861039 | DOI:10.2174/0113816128236536231010051130 (Source: Current Pharmaceutical Design)
Source: Current Pharmaceutical Design - October 20, 2023 Category: Drugs & Pharmacology Authors: Xiangwen Shi Yipeng Wu Haonan Ni Minzheng Guo Qi Cheng Yongqing Xu Source Type: research

Adverse events and drug-drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure
Expert Rev Cardiovasc Ther. 2023 Oct 19. doi: 10.1080/14779072.2023.2273900. Online ahead of print.ABSTRACTINTRODUCTION: Sodium glucoseco-transporter2-inhibitors(SGLT2-I), antihyperglycemic agents, are increasinglyprescribed in chronic heart failure(CHF). Their risk for drug-drug interactions(DDI)seems low. Safety-data derive mainly from diabetes-patients. This review aimsto summarize adverse-events(AE) and DDI of the SGLT2-I dapagliflozin,empagliflozin and sotagliflozin in patients with CHF.AREAS COVERED: Literature-search-terms inPubMed were 'adverse event/drug-drug interaction' and 'heart failure' AND'dapagliflozin' OR ...
Source: Expert Review of Cardiovascular Therapy - October 19, 2023 Category: Cardiology Authors: Claudia St öllberger Josef Finsterer Birke Schneider Source Type: research

Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia
Methicillin-resistant Staphylococcus aureus (MRSA) is responsible for an array of problematic community- and healthcare-acquired infections, including pneumonia, and is frequently associated with severe disease and high mortality rates. Standard recommended treatments for empiric and targeted coverage of suspected MRSA in patients with community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), are vancomycin and linezolid. However, adverse events such as acute kidney injury and Clostridium difficile infection have been associated with these antibiotics. Ceftar...
Source: European Respiratory Review - October 18, 2023 Category: Respiratory Medicine Authors: Torres, A., Kuraieva, A., Stone, G. G., Cilloniz, C. Tags: Pulmonary pharmacology and therapeutics, Respiratory infections and tuberculosis Reviews Source Type: research

Prevalence of potential drug-drug interactions among intensive care unit patients receiving linezolid: a cross-sectional study
CONCLUSIONS: ICU patients receiving linezolid have a high prevalence of potential drug-drug interactions, and efforts should be made to better recognize and manage this risk.PMID:37843351 | DOI:10.26355/eurrev_202310_33967 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - October 16, 2023 Category: Drugs & Pharmacology Authors: H-Y Jiang L-Y Yu X Wang Z-W Yu Y-H Zhao Source Type: research